Skip to main content
Clinical Trials/NCT00390819
NCT00390819
Unknown
Not Applicable

Epidemiology of Community Acquired Pneumonia in North Israel

HaEmek Medical Center, Israel1 site in 1 country100 target enrollmentNovember 2006

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Community Acquired Pneumonia
Sponsor
HaEmek Medical Center, Israel
Enrollment
100
Locations
1
Last Updated
19 years ago

Overview

Brief Summary

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality and is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen.

Aim of study: To identify common pathogens causing CAP in hospitalized patients in north Israel.

Detailed Description

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality. CAP is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen. CAP is divided to two principal groups: Bacterial CAP and Atypical CAP. Since pathogens are different, treatment approach is also different. The main obstacle is absence of adequate diagnostic immediate and cheap tools to enable identifying pathogen and hence treatment is not always appropriate. Giving the right therapy at the right time is of major importance since early start of correct treatment is linked to morbidity and mortality of patients. For prescribing appropriate empiric therapy, knowing the epidemiology of CAP, i.e. the frequent causing pathogens according to age groups and other demographic characteristics, is essential. Unfortunately, except one study conducted 10 years ago by Dr. Liberman from Soroka Medical Center, there is no characteristic information regarding causing pathogens. Lacking this data, might result in selecting inadequate treatment. Material \& Methods: We should enroll about 300 patients hospitalized in Ha'Emek Medical Center with the diagnosis of CAP, in order to make the study results statistically significant. In addition to demographic and clinical data, following tests will be performed: 1. Blood cultures 2. Sputum 3. PCR - throat culture to the following pathogens: * Mycoplasma pneumoniae * Chlamydia pneumoniae * Legionella * Adenovirus * Influenza A * Influenza B * RSV * Metapneumovirus * Parainfluenza * Pneumococcal antigen in urine

Registry
clinicaltrials.gov
Start Date
November 2006
End Date
TBD
Last Updated
19 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Community acquired pneumonia
  • Hospitalization

Exclusion Criteria

  • Immunocompromised patients
  • Patients under chemotherapy treatment
  • Patients under steroids treament

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials